Eli Lilly and Company CEDEAR

Eli Lilly and Company CEDEAR is a depositary certificate representing shares of a leading global biopharmaceutical firm through the Argentine market infrastructure. Its primary purpose is to provide local investors access, in local custody and settlement, to the economic rights of Eli Lilly and Company, including price performance and dividends, translated to the CEDEAR ratio structure. The underlying company discovers, develops, and commercializes prescription medicines across endocrinology and metabolic disorders, obesity, diabetes, oncology, immunology, neuroscience, and gastroenterology, with a portfolio that includes notable therapies for diabetes and weight management as well as targeted cancer treatments. Within Argentina’s market, this CEDEAR sits in the health technology sector classification and offers exposure to a mega-cap pharmaceutical issuer without requiring direct foreign listing access. The instrument is tied to an established issuer founded in 1876 and headquartered in Indianapolis, reflecting the performance and corporate actions of the underlying while trading and settling under local market conventions and identifiers, including an Argentina ISIN and BCBA listing framework.